Background/Aims: This study aims to investigate the effect of CD47 on the development of laryngeal squamous cell carcinoma (LSCC) and the therapeutic potential of monoclonal antibody against CD47 and its ligand SIRPα in the treatment of LSCC. Methods: We firstly detected the expressions of CD47 mRNA and protein in LSCC and para-carcinoma tissues, introduced the most efficient CD47siRNA sequence into LSCC cells by lentiviral transfection and employed three monoclonal antibodies to evaluate their anti-LSCC effects in vitro and in vivo. Results: We observed that the mRNA and protein expressions of CD47 in LSCC tissue had significant increase in LSCC tissues compared with those in para-carcinoma tissue (p < 0.05). After the treatments of three monoclonal antibodies, i.e. anti-SIRPα, anti-CD47 BRIC126, anti-CD47 B6H12.2, in rats transfected with Hep-2 cell, it has been showed that the mRNA and protein expressions of CD47 in LSCC tissue decreased, macrophage efficiency was promoted when anti-SIRPα and/or CD47siRNA were used, the amounts, viabilities and expressions of CD47 protein of tumor cell were significantly inhibited. Additionally, combined use of CD47siRNA and anti-SIRPα seemed more efficient than solo use of CD47siRNA/anti-SIRPα. Conclusion: The results suggested a critical role of CD47 in LSCC development and the promising treatment of antiCD47/SIRPα and/or CD47siRNA in LSCC.
CD47 is a Potential Target for the Treatment of Laryngeal Squamous Cell Carcinoma
Multiple factors including tobacco background, alcohol consumption, gastroesophageal and biliary reflux, viral infection, dietary factors as well as radiation and individual predisposition impact the occurrence and development of LSCC [4] . The recurrence and metastasis of LSCC contribute mainly to the high mortality and are of major concern for human health. Timely diagnosis as earlier as possible will be beneficial for the improvements of LSCC treatment and prognosis [5] . Owing to the poor clinical outcome for patients with advanced LSCC, there is an urgent need to search for novel marker and therapeutic strategy for LSCC treatment. Cell-surface molecules preferentially expressed on LSCC compared to their normal counterparts are potential candidates of biomarker. Thus far, several molecules, including CD34, CD44, CD105, CD133 and CD147 [6] [7] [8] [9] , have been identified as favorable markers in the prediction of LSCC. In terms of the fact that it may be insufficient to predict LSCC with only single marker, more efficient ones need to be explored [5] . CD47 is a ubiquitously expressed immunoglobulin-like integrin-associated protein, originally discovered when it was copurified with the integrin αvβ3 from leukocytes and placenta [10] . CD47 has diverse functions including neutrophil migration, axon extension, and T cell costimulation [11] [12] [13] . Up till now, the role of CD47 in LSCC treatment remains largely unknown.
In this paper, we used lentiviral vector to transfect the Hep-2 cell with CD47siRNA and performed heterotopic transplantation in rat to observe the expressions of CD47 mRNA and protein and the phagocytosis efficiency through quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot and flow cytometry. Subsequently three monoclonal antibody were employed to evaluate their therapeutic effects on LSCC.
Materials and Methods
Tumor sample and cell line Human LSCC cells and normal laryngeal epithelial cells/para-carcinoma tissues were obtained from the second affiliated hospital of Nanchang university (Nanchang, Jiangxi, China). Hep-2 cells of LSCC were purchased from the cell bank of Chinese Academy of Sciences (Shanghai, China).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
The total RNA was isolated with RNA extraction kit-DP430 (TIANGEN, Beijing, China) according to the product's instructions, and quantified by a Nanodrop 2000 (Thermo Scientific, Wilmington, DE, USA) as described previously [14, 15] . Briefly, the RNA was reverse-transcribed into cDNA by One Step PrimeScript ® miRNA cDNA Synthesis Kit (Takara, Japan) based on the instructions which was processed in a reaction mixture (20 μL) including 10 μL 2×SYBR Fast qPCR Mix, 0.5 μL PCR Forward/Reverse Primer, 4.0 μL dH 2 O, and 5 μL cDNA template. Then the amplification was performed at 50°C for 120 s, 95°C for 120 s followed by 40 cycles of 95°C for 15 s and 60°C for 32 s on Applied Biosystems 7500 Fast Dx RealTime PCR Instrument (Thermo Scientific, Wilmington, DE, USA). The β-catenin was set as the reference control. The primer sequences were devised as follows: CD47, forward 5'CTTTGAAGAGATGAGCAGTG3', reverse 5'CGATGTGGGATCTAATTCTC3', the totle length was 265 bp; β-catenin, forward 5'TGGATCAGCAAGCAGGAGTA3', reverse 5'TCGGCCACATTGTGAACTTT3', the totle length was 275bp. Both sequences were synthesized by Sangon Biotech (Shanghai, China). The relative target gene expression was calculated as a fold change of 2 -ΔΔCt value as described before [16] .
Western blotting analysis
The target proteins were extracted by EpiQuik Total Histone Extraction Kit (Epigentek, Farmingdale, NY, USA) and quantified by a BCA Protein Quantification Kit (vazyma, Nanjing, Jiangsu, China) with bovine serum albumin (BSA) as standard as described previously [17, 18] . The sample (= 50 mg) containing target protein were processed by electrophoretic separation before being transferred to PVDF membrane (EMD Millipore, Billerica, MA, USA). The membrane was blocked by 5% milk solution for 2 h at room temperature and washed three times by TBST (Sigma-Aldrich, USA). The membrane was respectively incubated with the primary monoclonal mouse anti-human CD47 antibodies including BRIC126, B6H12.2, IgG1 and GAPDH (Ebiosciences), and the primary monoclonal rat anti-mouse SIRPα (BD PharMingen, San Jose, CA, USA) at 4°C overnight at a dilution of 1:500. The membrane was immersed in PBST containing 0.5% tween-20 with three times, and then incubated with secondary goat anti-rabbit antibody conjugated with horseradish peroxidase (ZSGB-BIO, Beijing, China) at 1:500 for 90 min at room temperatume. The proteins were exposed in ECL developing solution followed by the product's instructions (BestBio, Shanghai, China). The strip gray levels were quantified using Quantity one v4.62 software by normalizing to GAPDH as an internal control.
Small interfering RNA (siRNA) and transfection Three CD47siRNA sequences as well as one control siRNA sequence were obtained from GenePharma (Shanghai, China) as follows: CD47siRNA1, 5' GAT CCC GCC TCT TTG AAG ATG GAT AAG TTG ATA TCC GCT TAT CCA TCT TCA AAG AGG CGT TTT TTC CAAG 3'; CD47siRNA2, 5' GAT CCC GCT ACT GGC CTT GGT TTA ATT TTG ATA TCC GAA TTA AAC CAA GGC CAG TAG CTT TTT TCC AAG 3'; CD47siRNA3, 5' GAT CCC GCA TGG CCC TCT TCT GAT TTC TTG ATA TCC GGA AAT CAG AAG AGG GCC ATG CTT TTT TCC AAG 3'; control, 5' UUC UCC GAA CGU GUC ACG UTT ACG UGA CAC GUC CGG AGA ATT 3'. The plasmid was fused with the siRNA sequences listed above and transferred into E. coli to screen positive colonies in selective plates at 37°C for 20 h. The accuracy of inserted sequence was verified by PCR in the positive colonies. The Hep-2 cells were cultivated in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO 2 prior to transfection experiment. Subsequently, the Hep-2 cells were transfected with siRNAs using Lipofectamine TM2000 transfection reagent (Invitrogen Life Technologies, USA) according to the manufacturer's instructions for further 24 h incubation. The transfected cells were imaged by fluorescent microscope and the fluorescence intensity was measured using NIS-Elements Microscope Imaging Software (Nikon). The transfected cells were also used for analyses of flow cytomety, qRT-PCR and western blot. Based on the results, the CD47siRNA sequence with best silence efficiency was chosen for subsequent experiment.
In vitro phagocytosis assay
Human peripheral blood (8 ml) was collected from a healthy volunteer and diluted twp-fold with sterile PBS. Then the diluted blood was added up the lymphocyte separating solution and centrifuged for 20 min to pool the macrophage. The macrophage was cultivated in RPMI-1640 medium supplemented with 10 ng/mL rhGM-GSM and 10% FBS for nine days. Prior to the in vitro phagocytosis assay, macrophages were incubated in serum-free medium for 2 hours prior to adding LSCC cells which were labeled with 2.5 μM carboxy fluorescein diacetate succinimidyl ester (CFSE) according to the manufacturer's protocol (Invitrogen). Subsequently, the assay experiment was performed in a 24-well tissue culture plate (Falcon) in four groups described as follows: group A, LSCC (2 × 10 
Xenotransplantation and monoclonal anti-CD47/SIRPα therapy
The animal experiments in the present study were approved and performed in accordance to the animal care guidelines of the Second Affiliated Hospital of Nanchang University. Forty-eight BALB/c nude mice (20-22 g ) that were divided into four groups with 8 in each group were purchased from the animal center of Shanghai Biological Science Institution (Shanghai, China). All mice were housed in cages with food and water provided ad libitum at room temperature for at least a week feed prior to transplantation. For the construction of xenotransplantation model, the Hep-2 cells transfected with siRNA were firstly suspended in DMEM, and 2 × 10 7 cells were implanted subcutaneously into the back of foreleg with 0.2 ml per mice. The model was established if the diameter of tumor reached to 5 mm. After that, the monoclonal antibody therapy commenced with 60 nM intraperitoneal injections of anti-SIRPα, anti-CD47 BRIC126, anti-CD47 B6H12.2 and human isotype-matched IgG1 control for consecutive 15 days. Direct tumor dimension measurements were performed every three days. After 15 days of treatment, animals were sacrificed and tumors were resected and weighed to calculate tumor inhibitory rate which was equal to (tumor weight in control group -tumor weight in experimental group)/tumor weight in control group × 100%. Concomitantly, the tumor tissue and cells were used for qRT-PCR analysis, western blot assay and immunohistochemical examination. MTT assay LSCC Cells (3×103 per well) were incubated in RPMI 1640 medium supplemented with 10% FBS, 100 U of penicillin and 100 mg/ml of streptomycin (Gibco @ , Grand Island, NY, USA) in 96-well plates for 24 h of incubation. At the time point, 20 μg/mL MTT (Sigma-Aldrich, St. Louis, MO, USA) was added to each well and incubated for 4 h. After that, 200 μl DMSO (Sigma-Aldrich, St. Louis, MO, USA) was added into each well to solubilize the dye completely. Finally, a microplate spectrophotometer (BIOTEK, Winooski, VT, USA) was used to detect the absorption of each well at the wavelength of 490 nm.
Immunohistochemistry LSCC and para-carcinoma tissues para-carcinoma tissues were collected, sectioned into 4 μm each, fixed in 10% formalin, and embedded in paraffin. Sections were deparaffinized and rehydrated before 0.3% H 2 O 2 treatment, and then incubated with 10% goat serum, washed and incubated with the antiCD47 primary antibodies at 4°C overnight. After subsequent incubation at 37°C for 45 min, the sections were washed and incubated with secondary antibodies at room temperature for 1 h. Finally, the sections were washed and incubated with diaminobenzidine tetrachloride for 10 min, and counterstained with haematoxylin. The stained sections were imaged and the CD47 content in LSCC cell surface were detected by streptavidinperoxidase.
Statistical analysis
Unless indicated, all experiments were performed triplicate in three independent occasions. The data were presented as the mean ± standard deviation, processed by SPSS 17 (SPSS, Chicago, IL, USA), and evaluated using a two-tailed Student's t-test. P < 0.05 was considered as statistically significant.
Results

Expressions of CD47 mRNA and protein in LSCC tissue
To uncover the role of CD47 in LSCC, the comparison of the expressions of CD47 mRNA and protein in LSCC tissue with those in normal tissue were performed. As shown, the relative expression of CD47 mRNA (0.61 ± 0.12) in LSCC tissue had significant increase compared with that (0.24 ± 0.1) in para-carcinoma tissue (p < 0.05, Fig. 1A) . Likewise, the relative expression of CD47 protein (0.65 ± 0.1) in LSCC tissue had also significant elevation compared with that (0.21 ± 0.08) in para-carcinoma tissue (p < 0.05, Fig. 1B and 1C) . The increasing expressions of CD47 mRNA and protein in LSCC tissue demonstrate an important role of CD47 in LSCC development.
Lentiviral construction and siRNA transfection
Three siRNA sequences were devised, synthesized and transfected into Hep-2 cells in order to select the best one to silence CD47. After transfections, the three siRNA sequences inhibited the expressions of CD47 mRNA and protein significantly compared with the control (p < 0.05, Fig. 2 ). More importantly, the expressions of CD47 mRNA and protein were inhibited significantly by CD47siRNA3 than CD7siRNA1 and CD47siRNA2 (p < 0.05, Fig. 2) . From the fluorescent images, the three siRNA sequences were exhibited to be transfected into Hep-2 cells successfully with evident green fluorescence seen in the intracellular spaces of most Hep-2 cells (Fig. 3A) . Compared with the control, the fluorescence intensity of the three siRNA sequences were significantly enhanced (p < 0.05, Fig. 3B ). Meanwhile, the fluorescence intensity of CD47siRNA3 increased notably than those of CD47siRNA1 and CD47siRNA2 (p < 0.05, Fig. 3B ). Therefore, the silenced efficiency of CD47siRNA3 was the best and selected as the most efficient sequence for further experiments.
In vitro phagocytosis assay
To further clarify the transfection efficiency of CD47siRNA3 and the potential therapeutic effect of monoclonal antibody, in vitro phagocytosis assay was performed accordingly. Solo use of IgG1 was not helpful for phagocytosis (Fig. 4A) , and the phagocytic efficiency was improved when CD47 was silenced (Fig. 4C) . After treatments of CD47siRNA and/or monoclonal anti-SIRPα, however, the phagocytic potential was completely stimulated as there were visually plenty of macrophage with green fluorescence which were engulfing or have engulfed tumor cells (black arrows, Fig. 4B and 4D) . Further, we observed that the proportion of M1-type macrophage (49.62%) was nearly equal to that of M2-type macrophage (48.93%) in LSCC cells without anti-CD47/SIRPα monoclonal antibody treatment and CD47siRNA interference (Fig. 5A) . However, the proportion of M1-type macrophage increased to 81.85% and 56.81% along with the decreases of that of M2-type macrophage to 14.35% and 39.30% after incubations with anti-SIRPα or CD47siRNA3 (Fig. 5B and 5C ). The M1-type macrophage level (70.71%) was further promoted accompanying with the decline of M2-type macrophage level (8.68%, Fig. 5D ) when both CD47siRNA3 and monoclonal anti-SIRPα were used. These results suggested silencing CD47 was beneficial to inhibiting LSCC development, and anti-SIRPα monoclonal antibody might be potential alternatives to treat LSCC.
Anti-CD47/SIRPα monoclonal antibody therapy in vivo
Due to the better combined effect of CD47siRNA with anti-SIRPα in LSCC treatment, it is reasonable to further monitor the therapeutic effect of anti-CD47/SIRPα monoclonal antibody in combination with CD47siRNA in vivo. Three monoclonal antibodies were employed, i.e. anti-SIRPα, anti-CD47 BRIC126 anti-CD47 B6H12.2. It was evident that the tumor sizes were reduced in the treatments of the three antibodies (Fig. 6) . Compared with the treatment of IgG1, it could be observed that (i) the expressions of CD47 mRNA (Fig. 7A) and protein ( Fig. 7B and 7C ) in LSCC tissue were all significantly inhibited (p < 0.05), (ii) the amounts of tumor cell were also notably inhibited (Fig. 8A-D) , (iii) the LSCC were under relatively strict control (p < 0.05, Fig. 9A ), and (iv) the viabilities of tumor cell (Fig. 9B ) and the expressions of CD47 protein (Fig. 9C ) in tumor cell commenced to decline (p < 0.05) after the exposures to the three antibodies. Intriguingly, the tumor inhibitory rate of anti-SIRPα and anti-CD47 B6H12.2 were superior to that of anti-CD47 BRIC126 (p < 0.05). These results indicated that the combination of anti-CD47/SIRPα monoclonal antibodies with CD47siRNA could become promising in LSCC treatment.
Discussion
To our best knowledge, CD47 has not been investigated as a LSCC marker before. As a matter of fact, abnormal expression of CD47 has been found in hematopoietic stem cells and leukemia cells, human acute myeloid leukemia stem cells, hepatocellular carcinoma, ovarian clear cell carcinoma [19] [20] [21] [22] , etc. displaying that CD47 might be a prevalent marker in many types of cell, including cancer cell. CD47 is used as a "marker of self" to assist the immune system to eliminate the foreigners, conveying the "don't eat me" signal [23] . The success of the signal transmission depends on the interaction of CD47 with its receptor SIRPα on macrophages [24] , which can negatively adjust the process of phagocytosis [25] . As described previously, the red blood cells were phagocytized due to autonomous CD47 deficiency [26] . This mechanism has been supposed to be associated with macrophage inability to phagocytize tumor cells due to inappropriately increase of CD47 [19, 20] . We reported here the identification of significant expression increases of CD47 mRNA and protein in LSCC tissue compared with the para-carcinoma tissues (Fig. 1) , indicating that CD47 conferred a survival advantage to LSCC by escaping phagocytosis of macrophage.
As a versatile and widely-used transgenic technique, lentiviral transgenesis has been devised to efficiently transfer viral genome into mammalian chromosomes [27] . Small (short) interfering ribonucleic acids (siRNAs) are usually 19-21 base-pairs (bp) polyanionic macromolecules and can be introduced into mammalian cell to selectively silence the expression of the target genes [28] [29] [30] [31] . Compared with the control, the expressions of CD47 mRNA and protein were evidently inhibited in HEP-2 cell transfected with CD47siRNA ( Fig.  2-3) , inferring the inhibition of LSCC.
The therapeutic uses of anti-CD and/or SIRPα monoclonal antibody has been less reported in the treatment of LSCC [32, 33] . Currently employed antibody therapeutic methods function via inducing antibody-dependent cellular cytotoxicity (ADCC), breaking pivotal receptor-ligand interactions, or other unknown mechanisms [34] . As described in several reports, CD47-SIRPα interactions constituted the main barrier that restricted antibodymediated killing efficiency of tumor cells [35] [36] [37] [38] . Based on the results, we observed that the interaction of CD47 with SIRPα could be interrupted, at least partly, by CD47siRNA and anti-SIRPα (Fig. 4A-4D) . Surprisingly, the CD47siRNA-mediated interruption was much inferior to that mediated by anti-SIRPα (Fig. 4B and 4C) . As described previously, macrophages could be divided into two types: M1-type macrophage and M2-type macrophage [39] . The former could be potently employed to kill the tumor cells by secreting proinflammatory cytokines, whilst the latter could promote tumor occurrence [40] . Mounting evidences indicated that M2-type macrophage was predominant in many cancer types, and M2/M1 ratio could reflect pro-/anti-tumor microenvironment [41] [42] [43] [44] . In this study, the ratio of M2/M1 decreased from 0.99 without the use(s) of CD47siRNA3 and/or anti-SIRPα (Fig. 5A) to 0.18 (Fig. 5B), 0.69 (Fig. 5C ) and 0.12 ( Fig. 5D ) when anti-SIRPα, CD47siRNA3, and anti-SIRPα + CD47siRNA3 were employed respectively. These results suggested that the LSCC microenvironment experienced the transfers from pro-tumor to anti-tumor after the administrations of CD47siRNA3 and/or anti-SIRPα. Therefore, the silenced CD47 and anti-SIRPα monoclonal antibody might be potential approaches to treat LSCC via disrupting the interaction of CD47 with SIRPα which would promote phagocytosis.
After exposures to anti-CD47 antibody, i.e. B6H12.2 and BRIC126, however, it could be observed that the inhibitory effects were comparable to that mediated by anti-SIRPα ( Fig. 5-8 ). These results might remind us that we should further optimize the silencing efficiency in future experiments. The in vivo test was also supportive of this mechanism of action described above, the uses of three monoclonal antibodies, i.e. anti-SIRPα, anti-CD47 B6H12.2 and anti-CD47 BRIC126, resulted in diminished tumor size, elevated anti-tumor rate, decreased tumor vitality, and reduced CD47 expressions in tumor tissue and cells ( Fig.  5-8 ). It was exciting to find that CD47 has basically lost the inhibition on the phagocytosis of macrophage when CD47siRNA and anti-SIRPα were concomitantly administered ( Fig.  4D and 5D ), exhibiting more profound effect than the solo effect of CD47siRNA/anti-SIRPα on LSCC development. These results demonstrated monoclonal antibody could become a viable choice in LSCC treatment and the treatment effect would be more anticipated if the combination of CD47siRNA and anti-CD47/SIRPα monoclonal antibody was implemented.
In conclusion, this investigation determined a critical role of CD47 in LSCC tissue compared with its normal counterpart and established the rationale for the use of anti-CD47/SIRPα monoclonal antibody and/or CD47siRNA in the treatment of LSCC.
